Creabilis hires chief medical officer
Dr David Roblin joins the firm after holding leading roles at Pfizer and Bayer
Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years. He has held leadership roles at Pfizer and Bayer across a range of therapy areas in research, development and commercial roles.
At Pfizer, Roblin was most recently senior vice president, head of research and site head for European r&d. Before this, he was head of anti-infectives at Bayer Medical Affairs.
In addition Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a US$2bn public-private partnership with the European Commission.
You may also like
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Pharmaceutical
![Formulation freedom in clinical development: Why Fill2Weight matters]()
Formulation freedom in clinical development: Why Fill2Weight matters
As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Research & Development
![Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline]()
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline
The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Pharmaceutical
![Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate]()
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate
The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar across key global markets
Pharmaceutical
![Pouching solutions for sterile and moisture-sensitive devices]()
Pouching solutions for sterile and moisture-sensitive devices
Sterile pouch loading and sealing is far more complex than a conventional packaging operation: When the pouch itself becomes the primary sterile barrier (and the product is filled aseptically) the packaging process must be engineered with the same level of care as the filling operation itself